StockData
Spruce Biosciences, Inc. logo

Spruce Biosciences, Inc. (SPRB) stock

SPRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/30
$40.49−1.76 (-4.17%)

Close on Nov 17, 2026Market cap $116.37MP/E –Yield –

Spruce Biosciences operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Spruce Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$42.62M. For fiscal 2025 it was -$33.33M. The highest annual figure on record is -$12.62M in fiscal 2019.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$33.33M–
FY2024Dec 31, 2024-$55.96M–
FY2023Dec 31, 2023-$33.28M–
FY2022Dec 31, 2022-$41.68M–
FY2021Dec 31, 2021-$35.88M–
FY2020Dec 31, 2020-$27.52M–
FY2019Dec 31, 2019-$12.62M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$22.12M–
Q1 FY2026Mar 31, 2026-$8.73M–
Q4 FY2025Dec 31, 2025-$6.46M–
Q3 FY2025Sep 30, 2025-$5.32M–
Q2 FY2025Jun 30, 2025-$8.83M–
Q1 FY2025Mar 31, 2025-$12.73M–
Q4 FY2024Dec 31, 2024-$20.68M–
Q3 FY2024Sep 30, 2024-$9.22M–
Q2 FY2024Jun 30, 2024-$11.11M-657.3%
Q1 FY2024Mar 31, 2024-$14.96M–
Q4 FY2023Dec 31, 2023-$11.21M–
Q3 FY2023Sep 30, 2023-$12.27M–
Q2 FY2023Jun 30, 2023$1.99M–
Q1 FY2023Mar 31, 2023-$11.79M–
Q4 FY2022Dec 31, 2022-$11.74M–
Q3 FY2022Sep 30, 2022-$8.58M–
Q2 FY2022Jun 30, 2022-$9.54M–
Q1 FY2022Mar 31, 2022-$11.83M–
Q4 FY2021Dec 31, 2021-$9.80M–
Q3 FY2021Sep 30, 2021-$7.60M–
Q2 FY2021Jun 30, 2021-$9.69M–
Q1 FY2021Mar 31, 2021-$8.79M–
Q4 FY2020Dec 31, 2020-$9.27M–
Q3 FY2020Sep 30, 2020-$7.60M–
Q2 FY2020Jun 30, 2020-$4.70M–
Q1 FY2020Mar 31, 2020-$5.96M–
Q4 FY2019Dec 31, 2019-$2.91M–

More Spruce Biosciences figures

See a number that looks wrong?